Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not shown the same effect on macrovascular complications.
This study evaluates the results of alogliptin compared with placebo in patients with type 2 diabetes who had a recent acute coronary syndrome. The primary endpoint was combined cardiovascular death, heart attack and stroke. 5280 patients were randomized to alogliptin versus placebo followed for 40 months. The primary end point occurred in 11.3% of alogliptin group versus 11.8% in the placebo group. The glycosylated hemoglobin level was significantly lower in the alogliptin branch. The incidence of hypoglycemia, cancer, pancreatitis, and hemodialysis were similar in both groups.
Conclusion:
In patients diagnosed with type 2 diabetes and recent acute coronary syndrome, treatment with alogliptin resulted in a rate of death, myocardial infarction and stroke similar to placebo.
William B. White
2013-09-02
Original title: Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
